Paper · 2199829

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.

Slebos RJ and 9 others. N Engl J Med, 1990. Cited by 725 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. Papers, record 2199829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2199829

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.; PubMed
Journal: N Engl J Med; PubMed
Year: 1990; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/2199829/; PubMed
DOI: https://doi.org/10.1056/nejm199008303230902; PubMed
The journal: https://conductscience.org/library/journal-index/0255562; PubMed
Citations, by iCite: 725; iCite
Relative citation ratio, by iCite: 15.7; iCite
Revised in PubMed: 2022-03-11; PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Slebos RJ	R J
2	Kibbelaar RE	R E
3	Dalesio O	O
4	Kooistra A	A
5	Stam J	J
6	Meijer CJ	C J
7	Wagenaar SS	S S
8	Vanderschueren RG	R G
9	van Zandwijk N	N
10	Mooi WJ	W J

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Adenocarcinoma	Major topic
Genes, ras	Major topic
Lung Neoplasms	Major topic
Adult
Aged
Aged, 80 and over
DNA, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Prognosis
Survival Rate

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by209

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 725 citations.

PMID	Title	Journal	Year	In Papers	Source
41,906,287	Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non-Squamous Non-Small Cell Lung Cancer (Non-SQ NSCLC) Patients in Queensland, Australia From 2014-2023.	Thorac Cancer	2026	https://conductscience.org/library/papers/41906287	PubMed
40,799,440	First-line immunotherapy in advanced non-squamous non-small cell lung cancer patients with rare mutations: a retrospective cohort study.	Transl Lung Cancer Res	2025	https://conductscience.org/library/papers/40799440	PubMed
40,243,851	HRAS Mutations in Head and Neck Carcinomas in Japanese Patients: Clinical Significance, Prognosis, and Therapeutic Potential.	Int J Mol Sci	2025	https://conductscience.org/library/papers/40243851	PubMed
39,534,096	Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research.	Front Oncol	2024	https://conductscience.org/library/papers/39534096	PubMed
39,522,047	RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.	J Hematol Oncol	2024	https://conductscience.org/library/papers/39522047	PubMed
39,468,056	Chemoproteogenomic stratification of the missense variant cysteinome.	Nat Commun	2024	https://conductscience.org/library/papers/39468056	PubMed
39,360,933	An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.	Future Oncol	2024	https://conductscience.org/library/papers/39360933	PubMed
39,309,861	A new model for the inference of biological entities states: Ternary Entity State Inference System.	Heliyon	2024	https://conductscience.org/library/papers/39309861	PubMed
38,994,972	Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy.	Cells	2024	https://conductscience.org/library/papers/38994972	PubMed
38,902,927	Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer.	HGG Adv	2024	https://conductscience.org/library/papers/38902927	PubMed

1 to 10 of 209

See all 209 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
KRAS	3,845	PubTator's text mining	https://conductscience.org/library/genes/3845

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2199829

GET https://conductscience.org/api/papers/v1/2199829/cited_by?page=2

API reference For AI assistants